Inovio Pharmaceuticals, Inc., together with its subsidiaries,
discovers, develops, and develops synthetic vaccines and immune
therapies focusing on cancers and infectious diseases. The company’s
DNA-based SynCon technology designed to provide protection against known
and new unmatched strains of pathogens, such as influenza. Its
electroporation DNA delivery technology uses controlled electrical
pulses to enhance cellular DNA vaccine uptake. The company’s clinical
programs include HPV-caused pre-cancers and cancers, influenza, prostate
cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B
virus, HIV, and malaria vaccines. It is also advancing preclinical
research for a seasonal/pandemic influenza vaccine, as well as other
products.
Please take a look at the 1-year chart of INO (Inovio Pharmaceuticals, Inc.) below with my added notations:
INO peaked in February at almost $16 and lost about half of its value
from there. The stock seems to have bottomed out a bit over the last
(3) months. Over the last year the stock has commonly hit a very
important level of resistance at $12 (blue). The one time INO was able
to break through $12 the stock ultimately ran to $15+. If the stock can
break above $12 again, higher prices should follow.
The Tale of the Tape: INO has a key level of
resistance at $12. A long trade could be entered on a break through that
level. However, if you are bearish on the stock, a short trade could be
made on any rallies up to $12.
Please share this article
No comments:
Post a Comment